ABSTRACT
Objective: To retrospectively analyze the clinical data of 52 patients with coronavirus disease-2019 COVID-19 and explore the clinical efficacy of modified Sanxiaoyin on mild/moderate COVID-19 patients. Method(s): The propensity score matching method was used to collect the clinical data of mild or moderate COVID-19 patients enrolled in the designated hospital of the Second Hospital of Jingzhou from December 2019 to May 2020. A total of 26 eligible patients who were treated with modified Sanxiaoyin were included in the observation group,and the 26 patients treated with conventional method were the regarded as the control. The disappearance of clinical symptoms,disappearance time of main symptoms,efficacy on traditional Chinese medicineTCMsymptoms,hospitalization duration,laboratory test indicators,and CT imaging changes in the two groups were compared. Result(s): The general data in the two groups were insignificantly different and thus they were comparable. After 7 days of treatment,the disappearance rate of fever,cough, fatigue,dry throat,anorexia,poor mental state,and poor sleep quality in the observation group was higher than that in the control groupP<0.05,and the difference in the disappearance rate of expectoration and chest distress was insignificant. For the cases with the disappearance of symptoms,the main symptomsfever, cough,fatigue,dry throat,anorexia,chest distressdisappeared earlier in the observation group than in the control groupP<0.01. After 7 days of treatment,the scores of the TCM symptom scale of both groups decreasedP<0.01,and the decrease of the observation group was larger that of the control groupP<0.01. All patients in the two groups were cured and discharged. The average hospitalization duration in the observation group12.79+/-2.68dwas shorter than that in the control group15.27+/-3.11dP<0.01. The effective rate in the observation group92.31%,24/26was higher than that in the control group76.92%,20/26. After 7 days of treatment,the lymphocyteLYMcount increasedP<0.05,and white blood cellWBCcount and neutrophilNEUTcount decreased insignificantly in the two groups. Moreover,levels of C-reactive protein CRP,erythrocyte sedimentation rateESR,and procalcitoninPCTreduced in the two groups after treatmentP<0.01and the reduction in the observation group was larger than that in the control group P<0.01. Through 7 days of treatment,the total effective rate on pulmonary shadow in the observation group 90.00%,18/20was higher than that in the control group77.27%,17/22P>0.05and the improvement of lung shadow in the observation group was better than that in the control groupP<0.01. Conclusion(s):Modified Sanxiaoyin can significantly alleviate fever,cough,fatigue,anorexia,chest distress,poor sleep quality,and other symptoms of patients with mild or moderate COVID-19,improve biochemical indicators,and promote the recovery of lung function. This paper provides clinical evidence for the application of modified Sanxiaoyin in the treatment of mild or moderate COVID-19.Copyright © 2022, China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica. All rights reserved.
ABSTRACT
［］ Objective： To retrospectively analyze the clinical data of 52 patients with coronavirus disease-2019 （COVID-19） and explore the clinical efficacy of modified Sanxiaoyin on mild/moderate COVID-19 patients. Method： The propensity score matching method was used to collect the clinical data of mild or moderate COVID-19 patients enrolled in the designated hospital of the Second Hospital of Jingzhou from December 2019 to May 2020. A total of 26 eligible patients who were treated with modified Sanxiaoyin were included in the observation group，and the 26 patients treated with conventional method were the regarded as the control. The disappearance of clinical symptoms，disappearance time of main symptoms，efficacy on traditional Chinese medicine（TCM）symptoms，hospitalization duration，laboratory test indicators，and CT imaging changes in the two groups were compared. Result： The general data in the two groups were insignificantly different and thus they were comparable. After 7 days of treatment，the disappearance rate of fever，cough， fatigue，dry throat，anorexia，poor mental state，and poor sleep quality in the observation group was higher than that in the control group（P<0.05），and the difference in the disappearance rate of expectoration and chest distress was insignificant. For the cases with the disappearance of symptoms，the main symptoms（fever， cough，fatigue，dry throat，anorexia，chest distress）disappeared earlier in the observation group than in the control group（P<0.01）. After 7 days of treatment，the scores of the TCM symptom scale of both groups decreased（P<0.01），and the decrease of the observation group was larger that of the control group（P<0.01）. All patients in the two groups were cured and discharged. The average hospitalization duration in the observation group［（12.79±2.68）d］was shorter than that in the control group［（15.27±3.11）d］（P<0.01）. The effective rate in the observation group（92.31%，24/26）was higher than that in the control group（76.92%，20/26）. After 7 days of treatment，the lymphocyte（LYM）count increased（P<0.05），and white blood cell（WBC）count and neutrophil（NEUT）count decreased insignificantly in the two groups. Moreover，levels of C-reactive protein （CRP），erythrocyte sedimentation rate（ESR），and procalcitonin（PCT）reduced in the two groups after treatment（P<0.01）and the reduction in the observation group was larger than that in the control group （P<0.01）. Through 7 days of treatment，the total effective rate on pulmonary shadow in the observation group （90.00%，18/20）was higher than that in the control group（77.27%，17/22）（P>0.05）and the improvement of lung shadow in the observation group was better than that in the control group（P<0.01）. Conclusion：Modified Sanxiaoyin can significantly alleviate fever，cough，fatigue，anorexia，chest distress，poor sleep quality，and other symptoms of patients with mild or moderate COVID-19，improve biochemical indicators，and promote the recovery of lung function. This paper provides clinical evidence for the application of modified Sanxiaoyin in the treatment of mild or moderate COVID-19. © 2022, China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica. All rights reserved.